Brought to you by 
Forest pays AZ $210mm for all rights to Novexel candidate
27 Oct 2020
Executive Summary
Following its concurrently announced acquisition of antibiotics developer Novexel, AstraZeneca has agreed to hand over all rights for Novexel's lead broad-spectrum candidate NXL104 to Forest Laboratories for $210mm. The deal sees AZ both granting and receiving rights through what turns out to be a very complex transaction.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Forest pays AZ $210mm for all rights to Novexel candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice